Pila Pharma

Executive Summary

Pila Pharma AB is a clinical-stage biotechnology company developing XEN-D0501, an oral, potent, and selective TRPV1 antagonist, as a potential first-in-class treatment for type 2 diabetes, obesity, and the rare painful disease erythromelalgia. Founded in 2015 and based in Malmö, Sweden, the company leverages a novel mechanism targeting the TRPV1 ion channel, which plays a key role in metabolism and pain signaling. Preclinical data suggest XEN-D0501 may improve glycemic control and reduce body weight, offering a differentiated approach in the crowded metabolic disease space. The company is also exploring its use in erythromelalgia, a condition with no approved therapies, providing a high-value orphan drug opportunity. With a strong intellectual property position and a clear development path, Pila Pharma represents an early-stage investment opportunity with significant upside if clinical proof-of-concept is achieved. However, the company faces typical development risks, including financing needs and regulatory hurdles, as it transitions from preclinical to clinical testing.

Upcoming Catalysts (preview)

• H2 2026Preclinical efficacy data in obesity models70% success
• Q1 2027IND/CTA submission for type 2 diabetes60% success
• 2026Partnership or licensing deal for erythromelalgia30% success